285
Views
1
CrossRef citations to date
0
Altmetric
Review

Current and emerging treatment modalities for bacterial rhinosinusitis in adults: a comprehensive review

, , , ORCID Icon & ORCID Icon
Pages 2013-2022 | Received 09 Aug 2022, Accepted 11 Nov 2022, Published online: 21 Nov 2022

References

  • Patel ZM, Hwang PH. Acute bacterial rhinosinusitis. In: Durand ML, Deschler DG, editors. Infections of the ears, nose, throat, and sinuses. Berlin/Heidelberg Germany: Springer; 2018. p. 133–143.
  • Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015;152(2 Suppl):S1–S39.
  • Orlandi RR, Kingdom TT, Smith TL, et al., International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021;11(3): 213–739.
  • Kaplan A. Canadian guidelines for acute bacterial rhinosinusitis: clinical summary. Can Fam Physician. 2014;60(3):227–234.
  • Wald ER. Microbiology of acute and chronic sinusitis in children. J Allergy Clin Immunol. 1992;90(3 Pt 2):452–456.
  • Sande MA, Gwaltney JM. Acute community-acquired bacterial sinusitis: continuing challenges and current management. Clin Infect Dis. 2004 1;39(3):S151–S158.
  • Martu C, Martu MA, Maftei GA, et al. Odontogenic sinusitis: from diagnosis to treatment possibilities - A narrative review of recent data. Diagnostics. 2022;12(7):1600.
  • Koeller K, Herlemann DPR, Schuldt T, et al. Microbiome and culture based analysis of chronic rhinosinusitis compared to healthy sinus mucosa. Front Microbiol. 2018;9:643.
  • Bose S, Grammer LC, Peters AT. Infectious chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2016;4(4):584–589.
  • Boase S, Foreman A, Cleland E, et al. The microbiome of chronic rhinosinusitis: culture, molecular diagnostics and biofilm detection. BMC Infect Dis. 2013;13(1):210.
  • Ramakrishnan VR, Hauser LJ, Feazel LM, et al. Sinus microbiota varies among chronic rhinosinusitis phenotypes and predicts surgical outcome. J Allergy Clin Immunol. 2015;136(2):334–342.
  • Thanasumpun T, Batra PS. Endoscopically-derived bacterial cultures in chronic rhinosinusitis: a systematic review. Am J Otolaryngol. 2015;36(5):686–691.
  • Stein M, Caplan ES. Nosocomial sinusitis: a unique subset of sinusitis. Curr Opin Infect Dis. 2005;18(2):147–150.
  • Fokkens WJ, Lund VJ, Hopkins C, et al., European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(S29): 1–464.
  • Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012;54(8):e72–e112.
  • Arnstead N, Chan Y, Kilty S, et al. Choosing wisely Canada rhinology recommendations. J Otolaryngol Head Neck Surg. 2020;49(1):10.
  • Zhanel GG, Palatnick L, Nichol KA, et al. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian respiratory organism susceptibility study, 1997 to 2002. Antimicrob Agents Chemother. 2003;47(6):1875–1881.
  • Huang WH, Fang SY. High prevalence of antibiotic resistance in isolates from the middle meatus of children and adults with acute rhinosinusitis. Am J Rhinol. 2004;18(6):387–391.
  • Anon JB, Berkowitz E, Breton J, et al. Efficacy/safety of amoxicillin/clavulanate in adults with bacterial rhinosinusitis. Am J Otolaryngol. 2006;27(4):248–254.
  • Brook I, Foote PA, Hausfeld JN. Eradication of pathogens from the nasopharynx after therapy of acute maxillary sinusitis with low- or high-dose amoxicillin/clavulanic acid. Int J Antimicrob Agents. 2005;26(5):416–419.
  • Matho A, Mulqueen M, Tanino M, et al. High-dose versus standard-dose amoxicillin/clavulanate for clinically-diagnosed acute bacterial sinusitis: a randomized clinical trial. PLoS One. 2018;13(5):e0196734.
  • Lindbaek M, Hjortdahl P, Johnsen UL. Randomised, double blind, placebo controlled trial of penicillin V and amoxycillin in treatment of acute sinus infections in adults. BMJ. 1996;313(7053):325–329.
  • Hadley JA, Mösges R, Desrosiers M, et al. Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis. Laryngoscope. 2010;120(5):1057–1062.
  • Høsøien E, Lund AB, Vasseljen O. Similar effect of therapeutic ultrasound and antibiotics for acute bacterial rhinosinusitis: a randomised trial. J Physiother. 2010;56(1):29–32.
  • Jang TY, Kim YH. Recent updates on the systemic and local safety of intranasal steroids. Curr Drug Metab. 2016;17(10):992–996.
  • Osguthorpe JD. Adult rhinosinusitis: diagnosis and management. Am Fam Physician. 2001;63(1):69–76.
  • Bird J, Biggs TC, Thomas M, et al. Adult acute rhinosinusitis. BMJ. 2013;346(may10 1):f2687.
  • Adam P, Stiffman M, RL B Jr. A clinical trial of hypertonic saline nasal spray in subjects with the common cold or rhinosinusitis. Arch Fam Med. 1998;7(1):39–43.
  • Rabago D, Zgierska A, Mundt M, et al. Efficacy of daily hypertonic saline nasal irrigation among patients with sinusitis: a randomized controlled trial. J Fam Pract. 2002;51(12):1049–1055.
  • Braun JJ, Alabert JP, Michel FB, et al. Adjunct effect of loratadine in the treatment of acute sinusitis in patients with allergic rhinitis. Allergy. 1997;52(6):650–655.
  • Smith SS, Kim R, Douglas R. Is there a role for antibiotics in the treatment of chronic rhinosinusitis? J Allergy Clin Immunol. 2022;149(5):1504–1512.
  • Bhattacharyya N. Bacterial infection in chronic rhinosinusitis: a controlled paired analysis. Am J Rhinol. 2005;19(6):544–548.
  • Brook I. Microbiology of chronic rhinosinusitis. Eur J Clin Microbiol Infect Dis. 2016;35(7):1059–1068.
  • Tan BK, Klingler AI, Poposki JA, et al. Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois. J Allergy Clin Immunol. 2017;139(2):699–703.
  • Lux CA, Wagner Mackenzie B, Johnston J, et al. Antibiotic treatment for chronic rhinosinusitis: prescription patterns and associations with patient outcome and the sinus microbiota. Front Microbiol. 2020;11:595555.
  • Wallwork B, Coman W, Mackay-Sim A, et al. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryngoscope. 2006;116(2):189–193.
  • Zeng M, Long XB, Cui YH, et al. Comparison of efficacy of mometasone furoate versus clarithromycin in the treatment of chronic rhinosinusitis without nasal polyps in Chinese adults. Am J Rhinol Allergy. 2011;25(6):e203–e207.
  • Varvyanskaya A, Lopatin A. Efficacy of long-term low-dose macrolide therapy in preventing early recurrence of nasal polyps after endoscopic sinus surgery. Int Forum Allergy Rhinol. 2014;4(7):533–541.
  • Cazzola M, Page CP, Calzetta L, et al. Emerging anti-inflammatory strategies for COPD. Eur Respir J. 2012;40(3):724–741.
  • Orlandi RR, Kingdom TT, Hwang PH, et al. International consensus statement on allergy and rhinology: rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(1):S22–209.
  • Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50(1):1–12.
  • Head K, Chong LY, Hopkins C, et al. Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016;4(4):CD011992.
  • Scadding GK, Scadding GW. Biologics for chronic rhinosinusitis with nasal polyps (CRSwNP). J Allergy Clin Immunol. 2022;149(3):895–897.
  • Laidlaw TM, Buchheit KM. Biologics in chronic rhinosinusitis with nasal polyposis. Ann Allergy Asthma Immunol. 2020;124(4):326–332.
  • Thamboo A, Kilty S, Witterick I, et al. Canadian rhinology working group consensus statement: biologic therapies for chronic rhinosinusitis. J Otolaryngol Head Neck Surg. 2021;50(1):15.
  • Schwitzguébel AJ, Jandus P, Lacroix JS, et al. Immunoglobulin deficiency in patients with chronic rhinosinusitis: systematic review of the literature and meta-analysis. J Allergy Clin Immunol. 2015;136(6):1523–1531.
  • Aanaes K, Nielsen KG, Arndal E, et al. Autologous fibrin sealant co-delivered with antibiotics is a robust method for topical antibiotic treatment after sinus surgery. Acta Otolaryngol. 2021;141(2):181–186.
  • Cho DY, Lim DJ, Mackey C, et al. In-vitro evaluation of a ciprofloxacin- and ivacaftor-coated sinus stent against Pseudomonas aeruginosa biofilms. Int Forum Allergy Rhinol. 2019;9(5):486–492.
  • Lemiengre MB, van Driel ML, Merenstein D, et al. Antibiotics for acute rhinosinusitis in adults. Cochrane Database Syst Rev. 2018;9(9):CD006089.
  • Uyttebroek S, Onsea J, Metsemakers WJ, et al., The potential role of bacteriophages in the treatment of recalcitrant chronic rhinosinusitis. Antibiotics (Basel). 2021;10(6): 675.
  • Fong SA, Drilling A, Morales S, et al. Activity of bacteriophages in removing biofilms of Pseudomonas aeruginosa isolates from chronic rhinosinusitis patients. Front Cell Infect Microbiol. 2017;7:418.
  • Zhang G, Zhao Y, Paramasivan S, et al. Bacteriophage effectively kills multidrug resistant Staphylococcus aureus clinical isolates from chronic rhinosinusitis patients. Int Forum Allergy Rhinol. 2018;8(3):406–414.
  • Cervin AU. The potential for topical probiotic treatment of chronic rhinosinusitis, a personal perspective. Front Cell Infect Microbiol. 2018;7:530.
  • Huntley KS, Raber J, Fine L, et al. Influence of the microbiome on chronic rhinosinusitis with and without polyps: an evolving discussion. Front Allergy. 2021;2:737086.
  • Cope EK, Lynch SV. Novel microbiome-based therapeutics for chronic rhinosinusitis. Curr Allergy Asthma Rep. 2015;15(3):504.
  • Mårtensson A, Abolhalaj M, Lindstedt M, et al. Clinical efficacy of a topical lactic acid bacterial microbiome in chronic rhinosinusitis: a randomized controlled trial. Laryngoscope Investig Otolaryngol. 2017;2(6):410–416.
  • Endam LM, Alromaih S, Gonzalez E, et al. Intranasal application of Lactococcus lactis W136 is safe in chronic rhinosinusitis patients with previous sinus surgery. Front Cell Infect Microbiol. 2020;10:440.
  • Head K, Chong LY, Piromchai P, et al. Systemic and topical antibiotics for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016 26; 4(4): CD011994.
  • Suh JD, Kennedy DW. Treatment options for chronic rhinosinusitis. Proc Am Thorac Soc. 2011;8(1):132–140.
  • Szaleniec J, Gibała A, Pobiega M, et al. Exacerbations of chronic rhinosinusitis - microbiology and perspectives of phage therapy. Antibiotics (Basel). 2019;8(4):175.
  • Wozniak A, Nowak K, Wnuk J, et al. Chronic rhinosinusitis: microbiology and treatment of acute exacerbations in patients after endoscopic surgery. J Laryngol Otol. 2021;135(12):1088–1093.
  • Yaniv D, Stern D, Vainer I, et al. The bacteriology of recurrent acute exacerbations of chronic rhinosinusitis: a longitudinal analysis. Eur Arch Otorhinolaryngol. 2020;277(11):3051–3057.
  • Chapurin N, Wu J, Labby AB, et al., Current insight into treatment of chronic rhinosinusitis: phenotypes, endotypes, and implications for targeted therapeutics. J Allergy Clin Immunol. 2022;150(1): 22–32.
  • Bachert C, Hamilos DL. Are antibiotics useful for chronic rhinosinusitis? J Allergy Clin Immunol Pract. 2016;4(4):629–638.
  • Van Zele T, Gevaert P, Watelet JB, et al. Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis. J Allergy Clin Immunol. 2004;114(4):981–983.
  • Abreu NA, Nagalingam NA, Song Y, et al. Sinus microbiome diversity depletion and Corynebacterium tuberculostearicum enrichment mediates rhinosinusitis. Sci Transl Med. 2012 2; 4(151): 151ra124.
  • Kato A, Peters AT, Stevens WW, et al., Endotypes of chronic rhinosinusitis: relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches. Allergy. 2022;77(3): 812–826.
  • Cazzola M, Rogliani P, Aliberti S, et al. An update on the pharmacotherapeutic management of lower respiratory tract infections. Expert Opin Pharmacother. 2017;18(10):973–988.
  • White AT, Clark CM, Sellick JA, et al. Antibiotic stewardship targets in the outpatient setting. Am J Infect Control. 2019;47(8):858–863.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.